Quality Assurance, Compliance & Auditing Capabilities
Certified auditors and seasoned subject matter experts (SMEs) with extensive expertise in preparing clients for audits, regulatory body inspections, and other evaluations.
Meet our Quality Assurance, Compliance & Auditing Experts
Nathan Blazei, RAC, ASQ-CQA
HEAD OF QUALITY & REGULATORY AFFAIRS



Markets That Benefit from Our Quality Assurance, Compliance & Auditing Solutions
Combination Products
Our experts understand the interaction between devices and drug products. Our experience includes injectables, nasal, respiratory, and more.
Biologics & Cell and Gene Therapy Services
We understand why “the product is the process” and how to implement solutions to your unique challenges.




The Kymanox Quality Assurance, Compliance & Auditing Difference
Our CGMP, GCP, and GLP audits support the full product life cycle from raw material to finished product to patient use.

Experience + Approach
We have experience with novel, high-risk, complex products (e.g., biologic with multi-use auto-injector). This experience informs our risk-based approach to personalized support.

Flexibility & Agility
At Kymanox, we make it easy for clients to get the solutions they need, when they need it. Clients tell us our flexibility is one of the key reasons they keep coming back.

Best-in-Class Output
Kymanox is committed to following up on all audit findings and addressing all corrective actions — including best-in-class recommendations for remedy — with the audit sponsor and auditee.
Frequently Asked Quality Assurance, Compliance & Auditing Questions (FAQs)
My company is preparing to launch a new product to market. Do I need a Mock Pre-Approval Inspection (PAI)?
Mock PAIs are highly encouraged for companies preparing to introduce new products to market. With our highly skilled workforce, subject matter experts will perform a thorough review of production controls, quality management systems, materials management, and laboratory practices in accordance with applicable regulations and in conformance to product filings. Our mission is to identify deficiencies and aid in implementing solutions to ensure your product is approved commercially. Kymanox takes pride in our PAI track record; we've executed 15 successful pre-approval inspections with FDA approval granted post-inspection.
What standards do you follow when conducting audits?
Kymanox follows industry best practices in audit execution consistent with the American Society for Quality’s (ASQ’s) approach to quality auditing. Our team has created SOPs and procedures, including toolkits and checklists that provide everything needed for the auditing process.
How can we mitigate risks with on-site visits for our third-party vendors when travel conditions are suboptimal?
Kymanox offers virtual audits! We're able to reduce risk and continue quality oversight of your GxP service providers remotely. Virtual tours may be conducted of manufacturing areas, testing laboratories, and warehousing/distribution sites. Through our online interface, we're able to conduct personnel interviews and review documentation. Our clients are even able to participate in our virtual audits by simply logging in to our online meeting platform.
Read the Latest at Kymanox
Kymanox Acquires EU Based Anteris Medical and Anteris Helvetia
Leveraging the well-respected anteris brand and team, this acquisition extends Kymanox’s capabilities and geographic reach with a strong European presence
Friday, 03 February 2023
Morrisville, North Carolina, USA and Holzkirchen, Germany an...
Interview: Kymanox Executive Advisors Mathias Romacker, Fran DeGrazio & Paul Jansen
Kymanox Executive Advisors (KEAs) Mathias Romacker, Fran DeGrazio, and Paul Jansen sit down with Guy Furness to discuss what has driven Kymanox's rapid rise in the drug delivery space and what makes the consulting company's model so successful, as well...
Growing Happy Cells: Bioreactor Optimization
Biologics, including cell and gene therapies, have become a hot topic in the pharmaceutical industry as their therapeutic applications expand. Challenges of developing biologic drug products include scale-up for commercial manufacturing and production ...